Forward
by Design
Diode Bio co-develops and co-invests in our Pharma partner's funding-constrained Phase I–II clinical candidates — swiftly advancing medicines that would otherwise be deprioritised, delayed, or forgotten to waiting patients.
Critical medicines are being left behind
Promising assets in immunology and oncology are routinely deprioritised, delayed or shelved by Pharma — not for lack of scientific promise, but for lack of resources and R&D budgets.
The bottleneck isn't biology. It's bandwidth, capital allocation, and the complexity of navigating clinical trials across multiple geographies simultaneously.
out of every 10,000 compounds synthesized in lab make it to market
of all R&D costs related to clinical trials
for clinical trials and regulatory approval
each year in stranded assets across pharma pipelines
"Pharmaceutical R&D faces strict financial constraints driven by soaring costs and the looming $300 billion global patent cliff — developing a new medicine takes 10-15 years and costs roughly $2.6 billion, forcing companies to pivot resources."— IFPMA.org
Co-developing Pharma's underfunded assets
Working closely with our Partners to identify high-potential but funding-constrained clinical candidates, Diode Bio then funds the asset's clinical co-development (at-Risk to Diode) while giving the Partner flexibility to retain buyback options until after the completion of the trial.
Asset Finding
Our team leverages pharma contacts and monitors trial results & pipelines to source high-value Phase I–II assets.
Scientific Diligence
Multi-domain synthesis of pre-clinical, CMC, clinical, IP, regulatory and commercial data.
Asset Validation
Translational, competitive and APAC pathway analysis — validated against our SAB and investment criteria.
Statistical Analysis
Endpoint optimisation, adaptive design, and KM modelling — powered by real-world data integration.
CRO Oversight
Engaging CRO networks across APAC — real-time data quality, site performance and risk flagging.
Capital
We co-develop & co-invest directly — our financial success is wholly aligned to yours. Partners retain buyback options until successful trial outcomes.
- Non-dilutive co-investment partnership
- Fully aligned financial incentives
- Flexible, bespoke deal structures
- Capital + expertise move as one
Execution
Clinical operations, regulatory strategy, and programme leadership across US, EU and APAC — integrated under one roof.
- Multi-regional Phase I–II trial delivery
- Pre-built APAC site networks
- FDA, EMA, TGA, PMDA, NMPA fluency
- Embedded programme management
Speed
Faster to first patient, faster to clinical data, faster to decision. Time is never neutral in drug development.
- Rapid site activation protocols
- Disciplined go/no-go architecture
- Measurable timeline compression
- Decision efficiency at every gate
APAC: the clinical frontier
Asia-Pacific represents a structural advantage in early clinical development — patient access, regulatory flexibility, and cost-efficiency that Western programmes routinely underestimate.
Diode Bio's Singapore headquarters gives us operational access to the region's leading trial sites, health authorities, and investigator networks.
APAC Clinical Circuit Map
Active co-development network — Singapore HQ
Where the science is strongest
Our core focus area is on Immunology & Oncology where we have deep scientific and clinical expertise. We are opportunistic to adjacent therapeutic areas where strong science meets our co-development model.
-
Immunology
Autoimmune, inflammatory, and immune-mediated conditions across organ systems
-
Oncology
Solid tumours, haematological malignancies, and immuno-oncology combinations
-
Adjacent Areas
Opportunistic — where the science is compelling and the model is a fit
-
Phase I & II Only
First-in-human through proof of concept — the highest-leverage window in development
Moving forward medicines that matter
To be the clinical co-development leader and partner-of-choice for Pharma by driving innovation through clinical trial success.
Bring forward critical medicines to patients that would otherwise be deprioritised, delayed or forgotten — through expert co-development, genuine partnership, and relentless execution.
- Round Table — every voice, every decision, together
- Decision Efficiency — clarity at every inflection point
- Speed — time is not neutral in drug development
- Science First — the data leads, always
- Patient Impact — the ultimate measure of success
Clinical development executive with over 25 years of experience leading global clinical operations across oncology, immunology, neuroscience, vaccines, and cardiovascular disease. Formerly VP and Head of Global Clinical Operations APAC at Johnson & Johnson/Janssen, with prior leadership roles at MSD and SmithKline Beecham. Extensive expertise in multinational trial execution, operational strategy, and global drug development across Asia Pacific and international markets.
Physician-scientist and life sciences executive with over 15 years of experience spanning oncology drug development, business development, and healthcare innovation. Formerly with Johnson & Johnson, AstraZeneca, Novartis, and GSK, where he supported development of leading oncology therapies including Enhertu, Dato-DXd, and Lynparza, led strategic partnering activities, and managed a US$150 million innovation fund focused on emerging healthcare technologies.
Regulatory affairs executive with over 30 years of experience supporting pharmaceutical development and approvals across Asia Pacific, the Middle East, and Africa. Formerly Head of Regulatory Competency Center APMA at Sandoz, with prior leadership roles at Johnson & Johnson, Takeda, AbbVie, Parexel, and GE Healthcare. Extensive expertise in regulatory strategy, drug development, market access, and health authority engagement across global markets.
Physician-scientist, entrepreneur, and biotech investor with over 25 years of experience building and financing innovative healthcare companies. Co-founder of Hua Medicine and Imvaq Therapeutics, with prior investment roles at Venrock and Fidelity Asia Ventures. Trained at Cornell University and Harvard University, with expertise spanning company creation, oncology, immunology, venture investing, and strategic partnerships across the U.S. and Asia.
Pharmaceutical and biotechnology executive with over 30 years of experience in licensing, M&A, and strategic partnerships. Formerly SVP Global Business Development at Grünenthal, with senior leadership roles at Sanofi, Sandoz, Neuraxpharm, and GSK. Has led transactions exceeding US$3 billion across oncology, immunology, and specialty pharma, and currently advises biopharma companies and investors globally.
A Different Kind of Development Partner.
Reach out to explore how Diode Bio can unlock value in your pipeline — confidentially, and on your terms.